» Articles » PMID: 19949401

Lessons from 60 Years of Pharmaceutical Innovation

Overview
Specialty Pharmacology
Date 2009 Dec 2
PMID 19949401
Citations 275
Authors
Affiliations
Soon will be listed here.
Abstract

Despite unprecedented investment in pharmaceutical research and development (R&D), the number of new drugs approved by the US Food and Drug Administration (FDA) remains low. To help understand this conundrum, this article investigates the record of pharmaceutical innovation by analysing data on the companies that introduced the approximately 1,200 new drugs that have been approved by the FDA since 1950. This analysis shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it. This suggests that, contrary to common perception, the new-drug output is not depressed, but may simply reflect the limitations of the current R&D model. The implications of these findings and options to achieve sustainability for the pharmaceutical industry are discussed.

Citing Articles

Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape.

Manders E, van den Berg S, de Visser S, Hollak C Eur J Health Econ. 2024; .

PMID: 39495345 DOI: 10.1007/s10198-024-01731-w.


Advances and Challenges of Bioassembly Strategies in Neurovascular In Vitro Modeling: An Overview of Current Technologies with a Focus on Three-Dimensional Bioprinting.

Mancuso S, Bhalerao A, Cucullo L Int J Mol Sci. 2024; 25(20).

PMID: 39456783 PMC: 11506837. DOI: 10.3390/ijms252011000.


State of the Art in Sub-Phenotyping Midbrain Dopamine Neurons.

Basso V, Dobrossy M, Thompson L, Kirik D, Fuller H, Gates M Biology (Basel). 2024; 13(9).

PMID: 39336117 PMC: 11428604. DOI: 10.3390/biology13090690.


Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review.

Quinn T, Bruce A, Burt T, Dhaliwal K BMC Pulm Med. 2024; 24(1):425.

PMID: 39210357 PMC: 11363577. DOI: 10.1186/s12890-024-03193-5.


Prediction of leukemia peptides using convolutional neural network and protein compositions.

Ansar Khawaja S, Farooq M, Ishaq K, Alsubaie N, Karamti H, Montero E BMC Cancer. 2024; 24(1):900.

PMID: 39060972 PMC: 11282659. DOI: 10.1186/s12885-024-12609-8.


References
1.
Bonabeau E, Bodick N, Armstrong R . A more rational approach to new-product development. Harv Bus Rev. 2008; 86(3):96-102, 134. View

2.
Travis J . Science and commerce. Science by the masses. Science. 2008; 319(5871):1750-2. DOI: 10.1126/science.319.5871.1750. View

3.
DiMasi J, Hansen R, Grabowski H, Lasagna L . Cost of innovation in the pharmaceutical industry. J Health Econ. 1991; 10(2):107-42. DOI: 10.1016/0167-6296(91)90001-4. View

4.
Maurer S . Choosing the right incentive strategy for research and development in neglected diseases. Bull World Health Organ. 2006; 84(5):376-81. PMC: 2627355. DOI: 10.2471/blt.06.029835. View

5.
DiMasi J, Hansen R, Grabowski H . The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151-85. DOI: 10.1016/S0167-6296(02)00126-1. View